CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study

CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study

The published article identified low and zero (0%) PD-L1 expression and no lymph node involvement as biomarkers for selecting patients most likely to benefit from Multikine pre-surgery treatment

Study concludes Multikine represents the first neoadjuvant treatment in decades to demonstrate an overall survival benefit in biomarker-selected patients with locally advanced resectable oral cancer

Multikine neoadjuvant treatment also demonstrated a statistically significant improvement in progression-free survival with a 49% reduction in the risk of disease progression in the same biomarker-selected patients

CEL-SCI Corporation (NYSE American: CVM) today announced the publication of its study, "A Novel Neoadjuvant Immunotherapy Confers Improved Overall Survival in Oral Cancer Patients with Low Tumor PD-L1 Expression: The IT-MATTERS Clinical Trial – Prognostic Role of Tumor PD-L1 Expression," in the internationally recognized journal Oral Oncology.